Arántzazu Barquín

Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.

Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Inmaculada Fernández et al. · Journal of Clinical Oncology · 2020 · 43 citations

Molecular Characterization, Urology, Surgical Oncology +15

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

Angeles Alvarez Secord, Sharyn N. Lewin, Colin G. Murphy et al. · Annals of Oncology · 2024 · 29 citations

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Eun Young Kang, Joshua Millstein, Gordana Popović et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2021 · 22 citations · Full text

Tumor Biology, Medicine, Pathology +8

Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer

Miguel Quiralte, Arántzazu Barquín, Mónica Yagüe-Fernández et al. · Journal of Clinical Investigation · 2024 · 20 citations · Full text

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer

María Dolores Fenor, Sergio Ruiz‐Llorente, Juan Francisco Rodríguez-Moreno et al. · Clinical & Translational Oncology · 2022 · 18 citations

Urology, Mek Inhibitor Sensitivity, Medicine +5